New study checks safety of fabry drug replagal in indian patients

NCT ID NCT05067868

Recruiting now Disease control Sponsor: Shire Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 01, 2026 · Updated 21 times

Summary

This study looks at how safe Replagal is for Indian children and adults with Fabry disease, a rare genetic disorder. Five participants will receive the drug through an IV every 2 weeks for about a year. The main goal is to track any side effects or reactions to the treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FABRY DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

All India Institute of Medical Sciences (AIIMS)
RECRUITING

New Delhi, 110029, India

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Institute of Child Health
NOT_YET_RECRUITING

Kolkata, 700017, India

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••
Sir Gangaram Hospital
RECRUITING

New Delhi, 110060, India

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

FABRY DISEASE FABRY DISEASE